

Vivian A Fonseca

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4014850/publications.pdf>

Version: 2024-02-01

228
papers

15,991
citations

18482
62
h-index

17105
122
g-index

232
all docs

232
docs citations

232
times ranked

17096
citing authors

#	ARTICLE	IF	CITATIONS
1	Socioeconomic Factors Play a More Important Role than Clinical Needs in the Use of SGLT2 Inhibitors and GLP-1 Receptor Agonists in People With Type 2 Diabetes. <i>Diabetes Care</i> , 2022, 45, e32-e33.	8.6	3
2	Efficacy of iGlarLixi on 5-year risk of diabetes-related complications: A simulation study. <i>Journal of Diabetes and Its Complications</i> , 2022, 36, 108132.	2.3	2
3	DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases. <i>Journal of Diabetes and Its Complications</i> , 2022, 36, 108101.	2.3	23
4	KDIGO recommendations for the evaluation of glycemic control in advanced chronic kidney disease. <i>Kidney International</i> , 2022, 101, 420.	5.2	4
5	Menopausal hormone therapy and risk of cardiovascular events in women with prediabetes or type 2 diabetes: A pooled analysis of 2917 postmenopausal women. <i>Atherosclerosis</i> , 2022, 344, 13-19.	0.8	2
6	Potential Gains in Life Expectancy Associated With Achieving Treatment Goals in US Adults With Type 2 Diabetes. <i>JAMA Network Open</i> , 2022, 5, e227705.	5.9	15
7	Changes in body size phenotypes from childhood to adulthood and the associated cardiometabolic outcomes. <i>Diabetes Research and Clinical Practice</i> , 2022, 187, 109884.	2.8	2
8	Projected Impact of the Medicare Part D Senior Savings Model on Diabetes-Related Health and Economic Outcomes Among Insulin Users Covered by Medicare. <i>Diabetes Care</i> , 2022, 45, 1814-1821.	8.6	4
9	Therapieintensivierung bei mit basalunterstützter oraler Therapie (BOT) unkontrolliertem Typ-2-Diabetes: Subanalyse der SoliMix-Studie bei Teilnehmern in Europa. <i>Diabetologie Und Stoffwechsel</i> , 2022, , .	0.0	0
10	Therapieintensivierung bei mit basalunterstützter oraler Therapie (BOT) unkontrolliertem Typ-2-Diabetes: Nächtliche Hypoglykämien in der SoliMix-Studie. <i>Diabetologie Und Stoffwechsel</i> , 2022, , .	0.0	0
11	Therapieintensivierung bei Typ-2-Diabetespatienten mit basalunterstützter oraler Therapie (BOT): Hypoglykämien als Funktion des HbA1c in der SoliMix-Studie. <i>Diabetologie Und Stoffwechsel</i> , 2022, , .	0.0	0
12	Sex Differences in the Progression of Metabolic Risk Factors in Diabetes Development. <i>JAMA Network Open</i> , 2022, 5, e2222070.	5.9	18
13	The Joint Secular Trends of Sleep Quality and Diabetes Among US Adults, 2005-2018. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, 3152-3161.	3.6	2
14	Predicting incident heart failure among patients with type 2 diabetes mellitus: The <sc>DM&CURE</sc> risk score. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 2203-2211.	4.4	6
15	Diabetes control in Asian Americans â€” Disparities and the role of acculturation. <i>Primary Care Diabetes</i> , 2021, 15, 187-190.	1.8	12
16	Intensive Risk Factor Management and Cardiovascular Autonomic Neuropathy in Type 2 Diabetes: The ACCORD Trial. <i>Diabetes Care</i> , 2021, 44, 164-173.	8.6	31
17	Fatty liver index and left ventricular mass: prospective associations from two independent cohorts. <i>Journal of Hypertension</i> , 2021, 39, 961-969.	0.5	10
18	Rationale for the Use of Combination Injectable Therapy in Patients With Type 2 Diabetes Who Have High A1C (â‰¥9%) and/or Long Duration (>8 Years): Executive Summary. <i>Clinical Diabetes</i> , 2021, 39, 141-145.	2.2	1

#	ARTICLE	IF	CITATIONS
19	Effects of a 2-Year Primary Care Lifestyle Intervention on Cardiometabolic Risk Factors. <i>Circulation</i> , 2021, 143, 1202-1214.	1.6	24
20	Inpatient management and post-discharge outcomes of hyperkalemia. <i>Hospital Practice</i> (1995), 2021, 49, 273-279.	1.0	2
21	Sex differences in soluble prorenin receptor in patients with type 2 diabetes. <i>Biology of Sex Differences</i> , 2021, 12, 33.	4.1	10
22	Replacement of Sedentary Behavior by Various Daily-Life Physical Activities and Structured Exercises: Genetic Risk and Incident Type 2 Diabetes. <i>Diabetes Care</i> , 2021, 44, 2403-2410.	8.6	26
23	Economic burden of diabetes-related hypoglycemia on patients, payors, and employers. <i>Journal of Diabetes and Its Complications</i> , 2021, 35, 107916.	2.3	16
24	The diminishing cost-effectiveness of the newer glucose-lowering drug classes in the United States: 2010â€“2018. <i>Current Medical Research and Opinion</i> , 2021, 37, 1-6.	1.9	0
25	Early Menopause and Cardiovascular Disease Risk in Women With or Without Type 2 Diabetes: A Pooled Analysis of 9,374 Postmenopausal Women. <i>Diabetes Care</i> , 2021, 44, 2564-2572.	8.6	21
26	Prevalence of Metabolic Acidosis Among Patients with Chronic Kidney Disease and Hyperkalemia. <i>Advances in Therapy</i> , 2021, 38, 5238-5252.	2.9	5
27	Non-invasive diagnosis of nonalcoholic fatty liver disease in patients with type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2021, 35, 107978.	2.3	5
28	Birth weight modifies the relation between adulthood levels of insulin-like growth factor-1 and type 2 diabetes: a prospective cohort study. <i>BMJ Open Diabetes Research and Care</i> , 2021, 9, e001885.	2.8	3
29	Stroke prevention in diabetes with glucagon-like peptide-1 receptor agonists: A game-changer?. <i>Journal of Diabetes and Its Complications</i> , 2021, 35, 108075.	2.3	0
30	Optimizing treatment goals for long-term health outcomes among patients with type 2 diabetes mellitus. <i>BMJ Open Diabetes Research and Care</i> , 2021, 9, e002396.	2.8	4
31	The Association Between Baseline Insulin Treatment and Cardiovascular Events: A Meta-Analysis. <i>Journal of the Endocrine Society</i> , 2021, 5, bvaa193.	0.2	4
32	Patient-specific factors associated with use of diabetes self-management education and support programs in Louisiana. <i>BMJ Open Diabetes Research and Care</i> , 2021, 9, e002136.	2.8	6
33	Blockade of sodium-glucose cotransporter 2 suppresses high glucose-induced angiotensinogen augmentation in renal proximal tubular cells. <i>American Journal of Physiology - Renal Physiology</i> , 2020, 318, F67-F75.	2.7	30
34	Results of a Study Comparing Glycated Albumin to Other Glycemic Indices. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 677-687.	3.6	23
35	Pax4 Gene Delivery Improves Islet Transplantation Efficacy by Promoting Î² Cell Survival and Î±-to-Î² Cell Transdifferentiation. <i>Cell Transplantation</i> , 2020, 29, 096368972095865.	2.5	6
36	Realâ€“world evidence of the effectiveness on glycaemic control of early simultaneous versus later sequential initiation of basal insulin and glucagonâ€“like peptideâ€“1 receptor agonists. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 2295-2304.	4.4	6

#	ARTICLE	IF	CITATIONS
37	BMI is Associated with Coronavirus Disease 2019 Intensive Care Unit Admission in African Americans. Obesity, 2020, 28, 1798-1801.	3.0	24
38	Weight Loss in Underserved Patients – A Cluster-Randomized Trial. New England Journal of Medicine, 2020, 383, 909-918.	27.0	62
39	Impact of Quality Improvement (QI) Program on 5-Year Risk of Diabetes-Related Complications: A Simulation Study. Diabetes Care, 2020, 43, 2847-2852.	8.6	9
40	Baseline Vitamin D Status, Sleep Patterns, and the Risk of Incident Type 2 Diabetes in Data From the UK Biobank Study. Diabetes Care, 2020, 43, 2776-2784.	8.6	64
41	Diabetes medication regimens and patient clinical characteristics in the national patient-centered clinical research network, PCORnet. Pharmacology Research and Perspectives, 2020, 8, e00637.	2.4	8
42	Using the BRAVO Risk Engine to Predict Cardiovascular Outcomes in Clinical Trials With Sodium-Glucose Transporter 2 Inhibitors. Diabetes Care, 2020, 43, 1530-1536.	8.6	16
43	Using the RE-AIM framework to evaluate internal and external validity of mobile phone-based interventions in diabetes self-management education and support. Journal of the American Medical Informatics Association: JAMIA, 2020, 27, 946-956.	4.4	13
44	A Systematic Review of Cost-Effectiveness of Sodium-Glucose Cotransporter Inhibitors for Type 2 Diabetes. Current Diabetes Reports, 2020, 20, 12.	4.2	21
45	Impact of Simultaneous Versus Sequential Initiation of Basal Insulin and Glucagon-like Peptide-1 Receptor Agonists on HbA1c in Type 2 Diabetes: A Retrospective Observational Study. Diabetes Therapy, 2020, 11, 995-1005.	2.5	10
46	Comment on Segar et al. Machine Learning to Predict the Risk of Incident Heart Failure Hospitalization Among Patients With Diabetes: The WATCH-DM Risk Score. Diabetes Care 2019;42:2298-2306. Diabetes Care, 2020, 43, e25-e25.	8.6	1
47	Diabetes INSIDE: Improving Population HbA1c Testing and Targets in Primary Care With a Quality Initiative. Diabetes Care, 2020, 43, 329-336.	8.6	7
48	Safety of Liraglutide in Type 2 Diabetes and Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 465-473.	4.5	32
49	Reductions in Insulin Resistance are Mediated Primarily via Weight Loss in Subjects With Type 2 Diabetes on Semaglutide. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 4078-4086.	3.6	25
50	Variabilities in Childhood Cardiovascular Risk Factors and Incident Diabetes in Adulthood: The Bogalusa Heart Study. Diabetes Care, 2019, 42, 1816-1823.	8.6	6
51	When should fixed ratio basal insulin/glucagon-like peptide-1 receptor agonists combination products be considered?. Journal of Diabetes and Its Complications, 2019, 33, 107473.	2.3	7
52	Addressing Regional Differences in Diabetes Progression: Global Calibration for Diabetes Simulation Model. Value in Health, 2019, 22, 1402-1409.	0.3	13
53	Sex Differences in Cardiovascular Risk Profile From Childhood to Midlife Between Individuals Who Did and Did Not Develop Diabetes at Follow-up: The Bogalusa Heart Study. Diabetes Care, 2019, 42, 635-643.	8.6	32
54	Response by Mann et al to Letter Regarding Article, “Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease: Results From the LEADER Trial”. Circulation, 2019, 139, e1017-e1018.	1.6	1

#	ARTICLE	IF	CITATIONS
55	Potential Role of Metal Chelation to Prevent the Cardiovascular Complications of Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 2931-2941.	3.6	13
56	Post-ACA Racial Disparity of Eye Examinations Among the U.S. Noninstitutionalized Population With Diabetes: 2014-2015. <i>Diabetes Care</i> , 2019, 42, e70-e72.	8.6	0
57	Canagliflozin Prevents Intrarenal Angiotensinogen Augmentation and Mitigates Kidney Injury and Hypertension in Mouse Model of Type 2 Diabetes Mellitus. <i>American Journal of Nephrology</i> , 2019, 49, 331-342.	3.1	95
58	Dethroning the king?: The future of metformin as first line therapy in type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2019, 33, 462-464.	2.3	3
59	Estimating Quality of Life Decrements Due to Diabetes Complications in the United States: The Health Utility Index (HUI) Diabetes Complication Equation. <i>Pharmacoeconomics</i> , 2019, 37, 921-929.	3.3	35
60	Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm - 2019 Executive Summary. <i>Endocrine Practice</i> , 2019, 25, 69-101.	2.1	245
61	Effect of metformin on neurodegenerative disease among elderly adult US veterans with type 2 diabetes mellitus. <i>BMJ Open</i> , 2019, 9, e024954.	1.9	100
62	Type 2 Diabetes and Hypertension. <i>Circulation Research</i> , 2019, 124, 930-937.	4.5	136
63	GLP-1 Receptor in Pancreatic β -Cells Regulates Glucagon Secretion in a Glucose-Dependent Bidirectional Manner. <i>Diabetes</i> , 2019, 68, 34-44.	0.6	61
64	MON-160 Effect Of The Combination Conjugated Estrogens And Bazedoxifene On Glucose Homeostasis In Obese Postmenopausal Women: A Placebo-controlled Randomized Pilot Trial. <i>Journal of the Endocrine Society</i> , 2019, 3, .	0.2	0
65	174-LB: Impact of Quality Improvement (QI) Program on 5-Year Risk of Diabetes-Related Complications. <i>Diabetes</i> , 2019, 68, .	0.6	1
66	Promoting Successful Weight Loss in Primary Care in Louisiana (PROPEL): Rationale, design and baseline characteristics. <i>Contemporary Clinical Trials</i> , 2018, 67, 1-10.	1.8	20
67	Long-term outcomes associated with triple-goal achievement in patients with type 2 diabetes mellitus (T2DM). <i>Diabetes Research and Clinical Practice</i> , 2018, 140, 45-54.	2.8	15
68	Differential sex effects of systolic blood pressure and low-density lipoprotein cholesterol on type 2 diabetes: Life course data from the Bogalusa Heart Study. <i>Journal of Diabetes</i> , 2018, 10, 449-457.	1.8	7
69	Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease. <i>Circulation</i> , 2018, 138, 2908-2918.	1.6	88
70	Chelation therapy to prevent diabetes-associated cardiovascular events. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2018, 25, 258-266.	2.3	10
71	Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm - 2018 Executive Summary. <i>Endocrine Practice</i> , 2018, 24, 91-121.	2.1	388
72	Novel Risk Engine for Diabetes Progression and Mortality in USA: Building, Relating, Assessing, and Validating Outcomes (BRAVO). <i>Pharmacoeconomics</i> , 2018, 36, 1125-1134.	3.3	61

#	ARTICLE	IF	CITATIONS
73	American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease. Endocrine Practice, 2017, 23, 1-87.	2.1	766
74	Menopausal Hormone Therapy and Type 2 Diabetes Prevention: Evidence, Mechanisms, and Clinical Implications. Endocrine Reviews, 2017, 38, 173-188.	20.1	206
75	Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive type 2 Diabetes Management Algorithm “ 2017 Executive Summary. Endocrine Practice, 2017, 23, 207-238.	2.1	362
76	Biomedical Journals and Preprint Services: Friends or Foes?. Clinical Chemistry, 2017, 63, 453-458.	3.2	15
77	Differential Effects of Linagliptin on the Function of Human Islets Isolated from Non-diabetic and Diabetic Donors. Scientific Reports, 2017, 7, 7964.	3.3	10
78	Utility of existing diabetes risk prediction tools for young black and white adults: Evidence from the Bogalusa Heart Study. Journal of Diabetes and Its Complications, 2017, 31, 86-93.	2.3	7
79	Effects of Linagliptin on Pancreatic β Cells of Type 1 Diabetic Mice. Journal of the Endocrine Society, 2017, 1, 1224-1234.	0.2	1
80	Revisiting The Use of Pioglitazone in the Treatment of Type 2 Diabetes. Endocrine Practice, 2016, 22, 1343-1346.	2.1	8
81	Consensus Statement By The American Association Of Clinical Endocrinologists And American College Of Endocrinology On The Comprehensive Type 2 Diabetes Management Algorithm “ 2016 EXECUTIVE SUMMARY. Endocrine Practice, 2016, 22, 84-113.	2.1	405
82	Association of Urinary Biomarkers of Inflammation, Injury, and Fibrosis with Renal Function Decline: The ACCORD Trial. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 1343-1352.	4.5	85
83	Economic burden of hypoglycemia: Utilization of emergency department and outpatient services in the United States (2005“2009). Journal of Medical Economics, 2016, 19, 852-857.	2.1	15
84	What Are We Learning from the FDA-Mandated Cardiovascular Outcome Studies for New Pharmacological Antidiabetic Agents?. Current Diabetes Reports, 2016, 16, 94.	4.2	2
85	Will the Affordable Care Act (ACA) Improve Racial/Ethnic Disparity of Eye Examination Among US Working-Age Population with Diabetes?. Current Diabetes Reports, 2016, 16, 58.	4.2	7
86	Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Lixisenatide and Insulin Glargine, Versus Insulin Glargine in Type 2 Diabetes Inadequately Controlled on Metformin Monotherapy: The LixiLan Proof-of-Concept Randomized Trial. Diabetes Care, 2016, 39, 1579-1586.	8.6	72
87	PAX4 Gene Transfer Induces β -to- β Cell Phenotypic Conversion and Confers Therapeutic Benefits for Diabetes Treatment. Molecular Therapy, 2016, 24, 251-260.	8.2	42
88	Glycated Albumin at 4 Weeks Correlates with A1C Levels at 12 Weeks and Reflects Short-Term Glucose Fluctuations. Endocrine Practice, 2015, 21, 1195-1203.	2.1	27
89	Comparison of Glucose Lowering Effect of Metformin and Acarbose in Type 2 Diabetes Mellitus: A Meta-Analysis. PLoS ONE, 2015, 10, e0126704.	2.5	40
90	Benefits of timely basal insulin control in patients with type 2 diabetes. Journal of Diabetes and Its Complications, 2015, 29, 295-301.	2.3	43

#	ARTICLE	IF	CITATIONS
91	Association between Inflammation and Biological Variation in Hemoglobin A1c in U.S. Nondiabetic Adults. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 2364-2371.	3.6	70
92	Association Between Colchicine and Risk of Diabetes Among the Veterans Affairs Population With Gout. <i>Clinical Therapeutics</i> , 2015, 37, 1206-1215.	2.5	17
93	Surge in Newly Identified Diabetes Among Medicaid Patients in 2014 Within Medicaid Expansion States Under the Affordable Care Act. <i>Diabetes Care</i> , 2015, 38, 833-837.	8.6	80
94	Triple combination of insulin glargine, sitagliptin and metformin in type 2 diabetes: The EASIE post-hoc analysis and extension trial. <i>Journal of Diabetes and Its Complications</i> , 2015, 29, 134-141.	2.3	5
95	From guideline to patient: a review of recent recommendations for pharmacotherapy of painful diabetic neuropathy. <i>Journal of Diabetes and Its Complications</i> , 2015, 29, 146-156.	2.3	75
96	Update on Safety Issues Related to Antihyperglycemic Therapy. <i>Diabetes Spectrum</i> , 2014, 27, 92-100.	1.0	17
97	Racial Disparity of Eye Examinations Among the U.S. Working-Age Population With Diabetes: 2002-2009. <i>Diabetes Care</i> , 2014, 37, 1321-1328.	8.6	61
98	Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: Insights from a patient-level pooled analysis of six randomized clinical trials. <i>Journal of Diabetes and Its Complications</i> , 2014, 28, 399-405.	2.3	75
99	New Developments in Diabetes Management: Medications of the 21st Century. <i>Clinical Therapeutics</i> , 2014, 36, 477-484.	2.5	27
100	Achieving glycaemic targets with basal insulin in T2DM by individualizing treatment. <i>Nature Reviews Endocrinology</i> , 2014, 10, 276-281.	9.6	13
101	Advancing Basal Insulin Replacement in Type 2 Diabetes Inadequately Controlled With Insulin Glargine Plus Oral Agents: A Comparison of Adding Albiglutide, a Weekly GLP-1 Receptor Agonist, Versus Thrice-Daily Prandial Insulin Lispro. <i>Diabetes Care</i> , 2014, 37, 2317-2325.	8.6	186
102	The degree of retinopathy is equally predictive for renal and macrovascular outcomes in the ACCORD Trial. <i>Journal of Diabetes and Its Complications</i> , 2014, 28, 874-879.	2.3	19
103	Hospital Discharge Algorithm Based on Admission HbA1c for the Management of Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2014, 37, 2934-2939.	8.6	94
104	Reduced risk of hypoglycemia with once-daily glargine versus twice-daily NPH and number needed to harm with NPH to demonstrate the risk of one additional hypoglycemic event in type 2 diabetes: Evidence from a long-term controlled trial. <i>Journal of Diabetes and Its Complications</i> , 2014, 28, 742-749.	2.3	35
105	How to get your paper published paper: An editor's perspective. <i>Journal of Diabetes and Its Complications</i> , 2014, 28, 1-3.	2.3	0
106	Saxagliptin overview: special focus on safety and adverse effects. <i>Expert Opinion on Drug Safety</i> , 2013, 12, 103-109.	2.4	36
107	Metanx in Type 2 Diabetes with Peripheral Neuropathy: A Randomized Trial. <i>American Journal of Medicine</i> , 2013, 126, 141-149.	1.5	88
108	Active- and placebo-controlled dose-finding study to assess the efficacy, safety, and tolerability of multiple doses of ipragliflozin in patients with type 2 diabetes mellitus. <i>Journal of Diabetes and Its Complications</i> , 2013, 27, 268-273.	2.3	76

#	ARTICLE	IF	CITATIONS
109	Efficacy and safety of sitagliptin added to ongoing metformin and pioglitazone combination therapy in a randomized, placebo-controlled, 26-week trial in patients with type 2 diabetes. Journal of Diabetes and Its Complications, 2013, 27, 177-183.	2.3	48
110	Diabetes Mellitus in the Next Decade: Novel Pipeline Medications to Treat Hyperglycemia. Clinical Therapeutics, 2013, 35, 714-723.	2.5	5
111	Determinants of Weight Gain in the Action to Control Cardiovascular Risk in Diabetes Trial. Diabetes Care, 2013, 36, 2162-2168.	8.6	46
112	Salicylate (Salsalate) in Patients With Type 2 Diabetes. Annals of Internal Medicine, 2013, 159, 1.	3.9	219
113	The American Diabetes Association Diabetes Research Perspective. Diabetes, 2012, 61, 1338-1345.	0.6	14
114	Impact of Hypoglycemia Associated With Antihyperglycemic Medications on Vascular Risks in Veterans With Type 2 Diabetes. Diabetes Care, 2012, 35, 1126-1132.	8.6	93
115	Efficacy and Safety of the Once-Daily GLP-1 Receptor Agonist Lixisenatide in Monotherapy. Diabetes Care, 2012, 35, 1225-1231.	8.6	209
116	Insulin glargine versus sitagliptin in insulin-naïve patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicentre, randomised open-label trial. Lancet, The, 2012, 379, 2262-2269.	13.7	100
117	The American Diabetes Association Diabetes Research Perspective. Diabetes Care, 2012, 35, 1380-1387.	8.6	21
118	Overview of metformin: special focus on metformin extended release. Expert Opinion on Pharmacotherapy, 2012, 13, 1797-1805.	1.8	52
119	Glucose Control and Cardiovascular Outcomes in Individuals with Diabetes Mellitus. Heart Failure Clinics, 2012, 8, 513-522.	2.1	5
120	Economic burden of hypoglycemia in patients with Type 2 diabetes. Expert Review of Pharmacoeconomics and Outcomes Research, 2012, 12, 47-51.	1.4	31
121	Introduction. American Journal of Medicine, 2011, 124, S1-S2.	1.5	0
122	Incretin-Based Therapies in Complex Patients: Practical Implications and Opportunities for Maximizing Clinical Outcomes: A Discussion with Dr. Vivian A. Fonseca. American Journal of Medicine, 2011, 124, S54-S61.	1.5	17
123	Impact of thiazolidinedione safety warnings on medication use patterns and glycemic control among veterans with diabetes mellitus. Journal of Diabetes and Its Complications, 2011, 25, 143-150.	2.3	18
124	Ongoing Clinical Trials Evaluating the Cardiovascular Safety and Efficacy of Therapeutic Approaches to Diabetes Mellitus. American Journal of Cardiology, 2011, 108, 52B-58B.	1.6	22
125	Safety evaluation of colesevelam therapy to achieve glycemic and lipid goals in type 2 diabetes. Expert Opinion on Drug Safety, 2011, 10, 305-310.	2.4	11
126	Glycated hemoglobin A1c(HbA1c) and diabetes: a new era?. Current Medical Research and Opinion, 2011, 27, 7-11.	1.9	6

#	ARTICLE	IF	CITATIONS
127	Urinary Catalytic Iron in Obesity. Clinical Chemistry, 2011, 57, 272-278.	3.2	7
128	Therapeutic Approaches to Target Inflammation in Type 2 Diabetes. Clinical Chemistry, 2011, 57, 162-167.	3.2	102
129	Urinary Catalytic Iron in Patients with Type 2 Diabetes without Microalbuminuria—a Substudy of the ACCORD Trial. Clinical Chemistry, 2011, 57, 341-344.	3.2	5
130	Iron and Diabetes Revisited. Diabetes Care, 2011, 34, 1676-1677.	8.6	33
131	Time to Recovery in Diabetes and Comorbidities Following Hurricane Katrina. Disaster Medicine and Public Health Preparedness, 2010, 4, S33-S38.	1.3	16
132	The Effects of Salsalate on Glycemic Control in Patients With Type 2 Diabetes. Annals of Internal Medicine, 2010, 152, 346.	3.9	343
133	Initial Combination Therapy with Metformin and Colesevelam for Achievement of Glycemic and Lipid Goals Min Early Type 2 Diabetes. Endocrine Practice, 2010, 16, 629-640.	2.1	31
134	Bile Acid Sequestrants for Lipid and Glucose Control. Current Diabetes Reports, 2010, 10, 70-77.	4.2	68
135	Colesevelam lowers glucose and lipid levels in type 2 diabetes: the clinical evidence. Diabetes, Obesity and Metabolism, 2010, 12, 384-392.	4.4	124
136	Adding subcutaneous liraglutide to metformin reduces HbA1c more than adding oral sitagliptin in patients whose type 2 diabetes is poorly controlled with metformin alone. Evidence-Based Medicine, 2010, 15, 115-116.	0.6	3
137	Effects of Cardiac Autonomic Dysfunction on Mortality Risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial. Diabetes Care, 2010, 33, 1578-1584.	8.6	435
138	Changes in Prandial Glucagon Levels After a 2-Year Treatment With Vildagliptin or Glimepiride in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy. Diabetes Care, 2010, 33, 730-732.	8.6	76
139	The enigma of glucose and cardiovascular disease. Heart, 2010, 96, 649-651.	2.9	3
140	Hypoglycemia, Diabetes, and Cardiovascular Events. Diabetes Care, 2010, 33, 1389-1394.	8.6	374
141	Starting insulin therapy with basal insulin analog or premix insulin analog in T2DM: a pooled analysis of treat-to-target trials. Current Medical Research and Opinion, 2010, 26, 1621-1628.	1.9	21
142	The 11- β -Hydroxysteroid Dehydrogenase Type 1 Inhibitor INCB13739 Improves Hyperglycemia in Patients With Type 2 Diabetes Inadequately Controlled by Metformin Monotherapy. Diabetes Care, 2010, 33, 1516-1522.	8.6	281
143	Effects of β -blockers on glucose and lipid metabolism. Current Medical Research and Opinion, 2010, 26, 615-629.	1.9	122
144	Bile Acids and Metabolic Regulation. Diabetes Care, 2009, 32, S237-S245.	8.6	304

#	ARTICLE	IF	CITATIONS
145	Defining and Characterizing the Progression of Type 2 Diabetes. Diabetes Care, 2009, 32, S151-S156.	8.6	416
146	Impact of a Natural Disaster on Diabetes. Diabetes Care, 2009, 32, 1632-1638.	8.6	146
147	Insulin glargine reduces carotid intimal hyperplasia after balloon catheter injury in Zucker fatty rats possibly by reduction in oxidative stress. Molecular and Cellular Biochemistry, 2009, 330, 1-8.	3.1	12
148	Therapeutic targets to reduce cardiovascular disease in type 2 diabetes. Nature Reviews Drug Discovery, 2009, 8, 361-367.	46.4	39
149	Introduction. European Journal of Internal Medicine, 2009, 20, S301-S302.	2.2	0
150	Introduction. American Journal of Medicine, 2009, 122, S1-S2.	1.5	3
151	Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications. Kidney International, 2009, 75, 1272-1277.	5.2	280
152	Colesevelam hydrochloride: a bile acid sequestrant for glycemic control and treatment of dyslipidemia in Type 2 diabetes mellitus. Therapy: Open Access in Clinical Medicine, 2009, 6, 475-487.	0.2	1
153	Systematic Review: Glucose Control and Cardiovascular Disease in Type 2 Diabetes. Annals of Internal Medicine, 2009, 151, 394.	3.9	308
154	Complications of diabetes. , 2009, , 41-57.		0
155	Insulin Sensitizers and Cardiovascular Disease. , 2009, , 81-95.		0
156	Management of Type 2 Diabetes: Oral Agents, Insulin, and Injectables. Journal of the American Dietetic Association, 2008, 108, S29-S33.	1.1	23
157	Identification and Treatment of Prediabetes to Prevent Progression to Type 2 Diabetes. Clinical Cornerstone, 2008, 9, 51-61.	0.7	19
158	Beta-blockers have a beneficial effect upon endothelial function and microalbuminuria in African-American subjects with diabetes and hypertension. Journal of Diabetes and Its Complications, 2008, 22, 303-308.	2.3	21
159	Dipeptidyl Peptidase-4 as a New Target of Action for Type 2 Diabetes Mellitus: A Systematic Review. Cardiology Clinics, 2008, 26, 639-648.	2.2	34
160	The Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial and Hurricane Katrina: Lessons for managing clinical trials during and after a natural disaster. Contemporary Clinical Trials, 2008, 29, 756-761.	1.8	5
161	Cardiovascular events and insulin therapy: A retrospective cohort analysis. Diabetes Research and Clinical Practice, 2008, 81, 97-104.	2.8	14
162	Colesevelam HCl Improves Glycemic Control and Reduces LDL Cholesterol in Patients With Inadequately Controlled Type 2 Diabetes on Sulfonylurea-Based Therapy. Diabetes Care, 2008, 31, 1479-1484.	8.6	242

#	ARTICLE	IF	CITATIONS
163	Efficacy and Safety of Colesevelam in Patients With Type 2 Diabetes Mellitus and Inadequate Glycemic Control Receiving Insulin-Based Therapy. Archives of Internal Medicine, 2008, 168, 1531.	3.8	184
164	Intensive Treatment and Complications of Diabetes. , 2008, , 51-68.		0
165	Missing the Point: Substituting Exenatide for Nonoptimized Insulin: Going from bad to worse!. Diabetes Care, 2007, 30, 2972-2973.	8.6	22
166	DPP-4 inhibitors as a new target of action for Type 2 diabetes mellitus: a focus on vildagliptin. Expert Review of Endocrinology and Metabolism, 2007, 2, 567-572.	2.4	0
167	Body Weight Changes with β -Blocker Use: Results from GEMINI. American Journal of Medicine, 2007, 120, 610-615.	1.5	95
168	Rationale for the Use of Insulin Sensitizers to Prevent Cardiovascular Events in Type 2 Diabetes Mellitus. American Journal of Medicine, 2007, 120, S18-S25.	1.5	26
169	Oxidants in Chronic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2007, 18, 16-28.	6.1	242
170	The effects of insulin on the endothelium. Endocrinology and Metabolism Clinics of North America, 2007, 36, 20-26.	3.2	11
171	Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus. Diabetes Care, 2007, 30, 162-172.	8.6	577
172	Early identification and treatment of insulin resistance: Impact on subsequent prediabetes and type 2 diabetes. Clinical Cornerstone, 2007, 8, S7-S18.	0.7	37
173	Identification and Treatment of Prediabetes to Prevent Progression to Type 2 Diabetes. Clinical Cornerstone, 2007, 8, 10-20.	0.7	32
174	Insulin Resistance Syndrome and Its Vascular Complications. , 2007, , 375-393.		0
175	The Effectiveness of Intensive Glycemic Control for the Prevention of Vascular Complications in Diabetes Mellitus. Treatments in Endocrinology: Guiding Your Management of Endocrine Disorders, 2006, 5, 273-286.	1.8	25
176	The role of basal insulin therapy in patients with type 2 diabetes mellitus. Insulin, 2006, 1, 51-60.	0.2	16
177	Metabolic Syndrome and Heart Failure. Heart Failure Clinics, 2006, 2, 1-11.	2.1	3
178	Review Paper $\frac{1}{2}$ CME. Insulin Resistance, Diabetes, Hypertension, and Renin?Angiotensin System Inhibition: Reducing Risk for Cardiovascular Disease. Journal of Clinical Hypertension, 2006, 8, 713-722.	2.0	35
179	Effects of PPAR gamma agonists on cardiovascular function in obese, non-diabetic patients. Vascular Pharmacology, 2006, 45, 29-35.	2.1	29
180	Diabetes treatments have differential effects on nontraditional cardiovascular risk factors. Journal of Diabetes and Its Complications, 2006, 20, 14-20.	2.3	29

#	ARTICLE	IF	CITATIONS
181	Of Hopes and DREAMS: The Quest to Prevent Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 4762-4763.	3.6	1
182	The PROactive Studyâ€”The Glass Is Half Full. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 25-27.	3.6	17
183	Pioglitazone Restores Endothelial Function in Patients with Type 2 Diabetes Treated with Insulin. Metabolic Syndrome and Related Disorders, 2006, 4, 179-184.	1.3	10
184	Metabolic Syndrome and Type 2 Diabetes Mellitus. , 2006, , 41-78.		0
185	The Hurricane Katrina Aftermath and Its Impact on Diabetes Care: Observations from "ground zero": lessons in disaster preparedness of people with diabetes. Diabetes Care, 2006, 29, 158-160.	8.6	36
186	Endothelial and Erectile Dysfunction, Diabetes Mellitus, and the Metabolic Syndrome: Common Pathways and Treatments?. American Journal of Cardiology, 2005, 96, 13-18.	1.6	82
187	The impact of antidiabetic therapies on cardiovascular disease. Current Atherosclerosis Reports, 2005, 7, 50-57.	4.8	19
188	Metabolic Syndrome: Underrated or underdiagnosed?. Diabetes Care, 2005, 28, 1831-1832.	8.6	19
189	Evaluating the Cardiovascular Effects of the Thiazolidinediones and Their Place in the Management of Type 2 Diabetes in Relation to the Metabolic Syndrome. Metabolic Syndrome and Related Disorders, 2005, 3, 147-173.	1.3	3
190	Pharmacological Treatment of the Insulin Resistance Syndrome in People Without Diabetes. Metabolic Syndrome and Related Disorders, 2005, 3, 332-338.	1.3	0
191	The metabolic syndrome,hyperlipidemia, and insulin resistance. Clinical Cornerstone, 2005, 7, 61-72.	0.7	65
192	Potential Cardiovascular Benefits of Insulin Sensitizers. Endocrinology and Metabolism Clinics of North America, 2005, 34, 117-135.	3.2	11
193	Diabetes, prediabetes, and cardiovascular risk: Shifting the paradigm. American Journal of Medicine, 2005, 118, 939-947.	1.5	83
194	Rosiglitazone reduces serum homocysteine levels, smooth muscle proliferation, and intimal hyperplasia in Sprague-Dawley rats fed a high methionine diet. Metabolism: Clinical and Experimental, 2005, 54, 645-652.	3.4	41
195	Role of insulin secretagogues and insulin sensitizing agents in the prevention of cardiovascular disease in patients who have diabetes. Cardiology Clinics, 2005, 23, 119-138.	2.2	14
196	Pharmacological Treatment of the Insulin Resistance Syndrome in People Without Diabetes. Metabolic Syndrome and Related Disorders, 2005, 3, 260-266.	1.3	0
197	Metabolic Effects of Carvedilol vs Metoprolol in Patients With Type 2 Diabetes Mellitus and Hypertension. JAMA - Journal of the American Medical Association, 2004, 292, 2227.	7.4	710
198	Thiazolidinedione Use, Fluid Retention, and Congestive Heart Failure. Diabetes Care, 2004, 27, 256-263.	8.6	561

#	ARTICLE	IF	CITATIONS
199	Diabetic nephropathy and retinopathy. Medical Clinics of North America, 2004, 88, 1001-1036.	2.5	111
200	Mechanisms and therapeutic targets in type 2 diabetes mellitus. Drug Discovery Today Disease Mechanisms, 2004, 1, 151-157.	0.8	30
201	Differential association of birth weight with cardiovascular risk variables in African- Americans and Whites: The Bogalusa heart study. Annals of Epidemiology, 2004, 14, 258-264.	1.9	28
202	Prevalence of non-traditional cardiovascular disease risk factors among persons with impaired fasting glucose, impaired glucose tolerance, diabetes, and the metabolic syndrome: analysis of the Third National Health and Nutrition Examination Survey (NHANES III). Annals of Epidemiology, 2004, 14, 686-695.	1.9	131
203	A Comparison of Bedtime Insulin Glargine with Bedtime Neutral Protamine Hagedorn Insulin in Patients with Type 2 Diabetes: Subgroup Analysis of Patients Taking Once-Daily Insulin in a Multicenter, Randomized, Parallel Group Study. American Journal of the Medical Sciences, 2004, 328, 274-280.	1.1	57
204	Inflammation and emerging risk factors in diabetes mellitus and atherosclerosis. Current Diabetes Reports, 2003, 3, 248-254.	4.2	45
205	Effect of thiazolidinediones on body weight in patients with diabetes mellitus. American Journal of Medicine, 2003, 115, 42-48.	1.5	262
206	Is weight loss possible in patients treated with thiazolidinediones? Experience with a low-calorie diet. Current Medical Research and Opinion, 2003, 19, 609-613.	1.9	30
207	Association of Hypoglycemia and Cardiac Ischemia: A study based on continuous monitoring. Diabetes Care, 2003, 26, 1485-1489.	8.6	341
208	Clinical significance of targeting postprandial and fasting hyperglycemia in managing type 2 diabetes mellitus. Current Medical Research and Opinion, 2003, 19, 635-631.	1.9	90
209	Differential Effects of Peroxisome Proliferator Activator Receptor- α and β Ligands on Intimal Hyperplasia After Balloon Catheter-Induced Vascular Injury in Zucker Rats. Journal of Cardiovascular Pharmacology and Therapeutics, 2003, 8, 297-305.	2.0	38
210	Addition of Nateglinide to Rosiglitazone Monotherapy Suppresses Mealtime Hyperglycemia and Improves Overall Glycemic Control. Diabetes Care, 2003, 26, 1685-1690.	8.6	37
211	Acute and Prolonged Effects of Sildenafil on Brachial Artery Flow-Mediated Dilatation in Type 2 Diabetes. Diabetes Care, 2002, 25, 1336-1339.	8.6	238
212	Drugs Affecting Homocysteine Metabolism. Drugs, 2002, 62, 605-616.	10.9	108
213	Effects of the Thiazolidinediones on Cardiovascular Risk Factors. American Journal of Cardiovascular Drugs, 2002, 2, 149-156.	2.2	28
214	The effect of troglitazone on plasma homocysteine, hepatic and red blood cell S-adenosyl methionine, and S-adenosyl homocysteine and enzymes in homocysteine metabolism in Zucker rats. Metabolism: Clinical and Experimental, 2002, 51, 783-786.	3.4	37
215	Effects of thiazolidinediones on cardiovascular risk factors. Comprehensive Therapy, 2002, 28, 200-206.	0.2	2
216	Nonhypoglycemic Effects of Thiazolidinediones. Annals of Internal Medicine, 2001, 134, 61.	3.9	359

#	ARTICLE	IF	CITATIONS
217	Diagnosis and treatment of hyperhomocysteinemia. Current Atherosclerosis Reports, 2001, 3, 54-63.	4.8	4
218	Management of the insulin resistance syndrome. Current Diabetes Reports, 2001, 1, 140-147.	4.2	14
219	Effects of low-dose candesartan on the rate of re-endothelialisation following vascular wound healing. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2001, 2, S81-S83.	1.7	0
220	Hyperhomocysteinemia In Type 2 Diabetes Mellitus: Cardiovascular Risk Factors And Effect Of Treatment With Folic Acid And Pyridoxine. Endocrine Practice, 2000, 6, 435-441.	2.1	19
221	Effect of Metformin and Rosiglitazone Combination Therapy in Patients With Type 2 Diabetes Mellitus. JAMA - Journal of the American Medical Association, 2000, 283, 1695.	7.4	476
222	Effects of a high-fat sucrose diet on enzymes in homocysteine metabolism in the rat. Metabolism: Clinical and Experimental, 2000, 49, 736-741.	3.4	81
223	Pioglitazone. Drugs, 2000, 60, 344-345.	10.9	2
224	Hyperhomocysteinemia and the Endocrine System: Implications for Atherosclerosis and Thrombosis. Endocrine Reviews, 1999, 20, 738-759.	20.1	102
225	Insulin Resistance Syndrome. Southern Medical Journal, 1999, 92, 2-14.	0.7	35
226	Effect of Troglitazone on Fibrinolysis and Activated Coagulation in Patients With Non-Insulin-Dependent Diabetes Mellitus. Journal of Diabetes and Its Complications, 1998, 12, 181-186.	2.3	115
227	Plasma homocysteine concentrations are regulated by acute hyperinsulinemia in nondiabetic but not type 2 diabetic subjects. Metabolism: Clinical and Experimental, 1998, 47, 686-689.	3.4	114
228	Hyperhomocysteinemia following a methionine load in patients with non-insulin-dependent diabetes mellitus and macrovascular disease. Metabolism: Clinical and Experimental, 1996, 45, 133-135.	3.4	138